Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Clear (fast-acting, long-acting) insulin generally does not need to be mixed
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Multi-receptor agonists that target the glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors may improve outcomes in type 2 diabetes because this condition is linked to hyperglycemia and obesity
Am J Clin Nutr 8:540546
Abbreviations AMPK: AMP-activated protein kinase CNS: Central nervous system DIO: Diet-induced obesity FGF21: Fibroblast growth factor 21 GCGR: Glucagon receptor GIP: Glucose-dependent insulinotropic polypeptide GLP-1: Glucagon-like peptide 1 K ATP channel: ATP-sensitive potassium channel MBH: Mediobasal hypothalamus NAFLD: Non-alcoholic fatty liver disease PKA: Protein kinase A STZ: Streptozotocin References Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922) Pancreatic extracts in the treatment of diabetes mellitus
US$ 22.73
US$ 28.86
US$ 27.46
US$ 25.89
